Other equities analysts have also issued research reports about the company. Zacks Investment Research raised AveXis from a hold rating to a buy rating and set a $112.00 price objective for the company in a research note on Tuesday, October 24th. Jefferies Group upped their price objective on AveXis to $118.00 and gave the stock a buy rating in a research note on Thursday, October 12th. Goldman Sachs Group reaffirmed a buy rating and issued a $130.00 price objective on shares of AveXis in a research note on Friday, October 6th. UBS Group reaffirmed a buy rating and issued a $122.00 price objective (up previously from $95.00) on shares of AveXis in a research note on Tuesday, October 3rd. Finally, Citigroup upped their price objective on AveXis from $100.00 to $116.00 and gave the stock a buy rating in a research note on Monday, October 2nd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of Buy and an average price target of $111.67.
AveXis (NASDAQ AVXS) traded up $5.53 during trading hours on Monday, reaching $111.85. The company’s stock had a trading volume of 332,490 shares, compared to its average volume of 384,900. AveXis has a twelve month low of $50.56 and a twelve month high of $116.15. The company has a market capitalization of $3,580.00 and a price-to-earnings ratio of -20.04.
In related news, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $109.75, for a total transaction of $1,646,250.00. Following the completion of the transaction, the insider now directly owns 1,808,386 shares of the company’s stock, valued at $198,470,363.50. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $101.26, for a total value of $180,242.80. Following the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at $180,242.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 52,340 shares of company stock valued at $5,318,845. 18.60% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its stake in AveXis by 13.1% during the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after buying an additional 544,475 shares during the last quarter. BlackRock Inc. boosted its stake in AveXis by 34.7% during the second quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock valued at $189,069,000 after buying an additional 592,843 shares during the last quarter. Vanguard Group Inc. boosted its stake in AveXis by 31.8% during the second quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after buying an additional 380,396 shares during the last quarter. Janus Henderson Group PLC boosted its stake in AveXis by 52.2% during the third quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock valued at $99,363,000 after buying an additional 352,456 shares during the last quarter. Finally, State Street Corp boosted its stake in AveXis by 104.2% during the second quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after buying an additional 510,189 shares during the last quarter. 92.88% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “AveXis (AVXS) Rating Reiterated by BMO Capital Markets” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2018/01/10/avexis-avxs-rating-reiterated-by-bmo-capital-markets.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.